Legend Biotech to Participate in the Jefferies Virtual Cell Therapy Summit
Legend Biotech Corporation (NASDAQ: LEGN) will participate in the Jefferies Virtual Cell Therapy Summit on October 6th. Ying Huang, interim CEO and CFO, will represent the company during the session at 11:20 a.m. ET. The event can be accessed via the Legend Biotech website for investors and interested parties. Legend Biotech focuses on developing innovative cell therapies for oncology and other diseases, and is collaborating with Janssen Biotech on its lead candidate, ciltacabtagene autoleucel, which is undergoing clinical trials for multiple myeloma.
- None.
- None.
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the Jefferies Virtual Cell Therapy Summit on Tuesday, October 6th. Ying Huang, interim-Chief Executive Officer and Chief Financial Officer, will represent the Company in a session scheduled at 11:20 a.m. (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 700 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.
We are engaged in a strategic collaboration with Janssen Biotech, Inc. to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.
